# Deep Dive: The PFAS Substitution Risk Paradox in Medical Devices

Page: https://stenobird.com/podcast/let-s-talk-risk-podcast-6693844/deep-dive-the-pfas-substitution-risk-paradox-in-medical-devices
Text version: https://stenobird.com/podcast/let-s-talk-risk-podcast-6693844/deep-dive-the-pfas-substitution-risk-paradox-in-medical-devices.md
Podcast: [Let's Talk Risk! Podcast](https://stenobird.com/podcast/let-s-talk-risk-podcast-6693844)
Published: 2026-09-04T12:00:00+00:00
Episode link: https://naveenagarwalphd.substack.com/p/deep-dive-the-pfas-substitution-risk-paradox
Audio file: https://api.substack.com/feed/podcast/214090831/8702c185e17deea0f3659ae99e493eed.mp3
Processing state: not_requested
JSON: https://stenobird.com/v1/public/podcasts/let-s-talk-risk-podcast-6693844/episodes/deep-dive-the-pfas-substitution-risk-paradox-in-medical-devices
Duration seconds: 1226

## Resource

FDA: There is no reason to restrict the continued use of fluoropolymers in medical devices. What happens when pressure to eliminate a material creates greater risk for the patient? This Deep Dive examines the growing regulatory tension around PFAS and medical-device fluoropolymers , and why evaluating substitution requires more than asking whether a material belongs to a broad chemical category. Key highlights covered in the audio: * Not all PFAS present the same risk. The discussion distinguishes small-molecule PFAS from large, biostable fluoropolymers such as PTFE and PVDF used in medical devices. * FDA’s position is supported by extensive clinical experience. Decades of use and a large ECRI review found no conclusive evidence of patient harm from PTFE. * Substitution can introduce new clinical hazards. Changes in friction, flexibility, chemical resistance, sealing, or coating integrity can directly affect device performance and patient safety. * This creates a substitution risk paradox. Eliminating one perceived material hazard may introduce more immediate risks such as reduced trackability, altered drug delivery, particulate shedding, or embolic complications. * The decision belongs inside risk management. Under ISO 14971 , the key question is how substitution changes the device’s total risk profile—not simply whether the original material can be removed. * A defensible strategy requires evidence. Chemical characterization, toxicological assessment, clinical evidence, and post-market surveillance can support continued use of a proven material. Keywords: PFAS, Fluoropolymers, PTFE, Medical Devices, FDA, Material Substitution, ISO 14971, Benefit-Risk Assessment, Patient Safety, Risk Management 🎧 Listen to the Deep Dive for a closer look at why eliminating a perceived…

## Actions

- request_transcript: `POST https://stenobird.com/v1/public/podcasts/let-s-talk-risk-podcast-6693844/episodes/deep-dive-the-pfas-substitution-risk-paradox-in-medical-devices/transcription-requests` — Idempotently request low-priority transcript generation for this episode.
- read_markdown: `GET https://stenobird.com/podcast/let-s-talk-risk-podcast-6693844/deep-dive-the-pfas-substitution-risk-paradox-in-medical-devices.md` — Read the agent-friendly Markdown representation of this episode resource.

A page view does not enqueue transcription. Agents should invoke `request_transcript` explicitly when they need this episode processed.

## Transcript

Full transcripts are not published on public pages unless there is a clear rights basis.